Tokyo, Japan, Sept 13, 2005 - (JCNN) - Landmark data from the PROactive Study, presented September 13 at the 41st meeting of the European Association for the Study of Diabetes (EASD) demonstrated that
Takeda Pharmaceutical's ACTOS(R) (pioglitazone HCl) significantly reduces the combined risk of heart attacks, strokes and death by 16% in high risk patients with
type 2 diabetes.
The PROactive Study (Prospective Pioglitazone Clinical Trial In Macrovascular Events Study) showed that ACTOS (generic name: pioglitazone HCI), an oral antidiabetic agent, can reduce the risk of developing and dying of cardiovascular diseases including heart attack and strokes in type 2 diabetics.
The PROactive study is a randomized, double-blind, placebo-controlled outcome study that determines the effects of ACTOS in type 2 diabetics who have a history of heart attack, coronary-artery bypass surgery and stroke. The study was co-conducted by Takeda Pharmaceutical and Eli Lilly in 19 European countries involving 5,238 patients.
Source: JCN http://www.japancorp.net
Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
COPYRIGHT 2005 Gale Group
Contact
Home
A
8-Hour Bayer